Waters Corporation has announced the acquisition of Halo Labs, a company known for its specialized imaging technologies for detecting, identifying, and counting particles in therapeutic products. This acquisition aims to enhance Waters' biological analysis portfolio, particularly in the field of emerging biopharma therapies. By integrating Halo Labs' innovative low-sample-volume, high-throughput technology, Waters plans to provide more comprehensive analysis solutions for a range of sample types, aiding in the development and manufacturing of therapies like CAR T-cell treatments. The transaction is expected to have minimal impact on Waters' income statement over the next 12 months, while strategically positioning the company for growth in large molecule therapy analysis and testing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.